Bexarotene - Uses, Dosage, Side Effects, Interactions

Bexarotene is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL). Bexarotene is a retinoid, a member of benzoic acids, and a member of naphthalenes. It has a role as an antineoplastic agent. Bexarotene therapy is associated with a high rate of serum enzyme elevations and rare instances of clinically apparent acute liver injury.

Bexarotene is a synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic, and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)

Mechanism of Action

Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR_α, RXR_β, and RXR_γ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL. Bexarotene is a retinoid that selectively activates retinoid X receptors (RXRs), as opposed to the retinoic acid receptors, the other major target of retinoic acid (the acid form of vitamin A). By so doing it induces cell differentiation and apoptosis and prevents the development of drug resistance.^[rx] It also has anti-angiogenic effects and inhibits cancer metastasis.^[rx] The retinoic acid receptors (RARs) regulate cell differentiation and proliferation whereas RXRs regulate apoptosis.^[rx]

Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR(alpha), RXR(beta), RXR(gamma)). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptors, thyroid receptors, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.

Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biological activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR_α, RXR_β, RXR_γ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptors, thyroid receptors, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.

Indications

Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
Targretin capsules are indicated for the treatment of skin manifestations of advanced-stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
Refractory peripheral cutaneous T-cell lymphoma
Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in people who are refractory to at least one prior systemic therapy (oral) and for the topical treatment of cutaneous lesions in patients with CTCL who have refractory or persistent disease after other therapies or who have not tolerated other therapies (topical)

Use in Cancer

Bexarotene is approved to treat:

Skin problems caused by cutaneous T-cell lymphoma that cannot be treated or that did not respond to other treatments.

Bexarotene is also being studied in the treatment of other types of cancer.

Contraindications

Hypersensitivity to the active substance or to any of the excipients in the preparation(s).
Pregnancy and lactation
Women of child-bearing potential without effective birth-control measures
History of pancreatitis
Uncontrolled hypercholesterolemia
Uncontrolled hypertriglyceridemia
Hypervitaminosis A
Uncontrolled thyroid disease
Hepatic insufficiency
Ongoing systemic infection
a condition with low thyroid hormone levels
poor control of diabetes
high amount of triglyceride in the blood
low levels of white blood cells
alcoholism
clouding of the lens of the eye called cataracts
biliary and gallbladder problem
acute inflammation of the pancreas
abnormal liver function tests
pregnancy
a patient who is producing milk and breastfeeding

Dosage

Strengths: 75 mg

Cutaneous T-cell Lymphoma

300 mg/m2/day orally once a day with a meal
Duration of Therapy: This drug should be continued as long as the patient is a deriving benefits. In clinical trials with CTCL patients, this drug was administered for up to 118 weeks.
If there is no tumor response after 8 weeks of treatment and the initial dose was well-tolerated, the dose may be escalated to 400 mg/m2/day with careful monitoring.

Dose Adjustments

If Toxicity Occurs:

Reduce the dose to 200 mg/m2/day than to 100 mg/m2/day, or temporarily suspend treatment.
Carefully readjust the dose upward when toxicity is controlled.

If Fasting Triglycerides are Elevated or Become Elevated During Treatment:

Institute antilipemic therapy.
If necessary, reduce the dose to 200 mg/m2/day then to 100 mg/m2/day, or discontinue treatment.

Side Effects

The Most Common

headache
weakness
tiredness
increased sensitivity to cold
increase in weight
depression
joint or muscle pain
thin, brittle hair or fingernails
constipation
rash
dry skin
redness, scaling, or itching of the skin
hair loss
swelling of ankles, feet, and legs
difficulty falling asleep or staying asleep
nausea
vomiting
diarrhea
sudden or ongoing back or stomach pain
severe and ongoing nausea and vomiting
fever, sore throat, chills, or other signs of infection
changes in vision

More Common

skin reactions (mostly itchiness and rashes),
leucopenia,
headache,
weakness,
thyroid anomalies (which seem to be mediated by RXR-mediated downregulation of thyroid stimulating hormone) and
blood lipid anomalies such as hypercholesterolemia (high blood cholesterol) and
hyperlipidemia,
hypothyroidism.

Rare

blurred vision, eye pain, or seeing halos around lights;
low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, sore throat, cough, pale skin, cold hands and feet, feeling light-headed or short of breath;
pancreatitis–severe pain in your upper stomach spreading to your back, nausea and vomiting; or
signs of underactive thyroid–extreme tiredness, dry skin, constipation, feeling more sensitive to cold temperatures, weight gain.
low blood cell counts;
headache, weakness
nausea, stomach pain;
rash, dry skin; or
swelling in your hands or feet.

Drug Interactions

DRUG	INTERACTION
Abametapir	The serum concentration of Bexarotene can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Bexarotene can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Bexarotene.
Abemaciclib	The metabolism of Abemaciclib can be increased when combined with Bexarotene.
Abrocitinib	The metabolism of Abrocitinib can be decreased when combined with Bexarotene.
Acalabrutinib	The metabolism of Acalabrutinib can be increased when combined with Bexarotene.
Acenocoumarol	The metabolism of Acenocoumarol can be increased when combined with Bexarotene.
Acetohexamide	The metabolism of Acetohexamide can be decreased when combined with Bexarotene.
Acetyl sulfisoxazole	The metabolism of Bexarotene can be decreased when combined with Acetyl sulfisoxazole.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bexarotene.
Adalimumab	The metabolism of Bexarotene can be increased when combined with Adalimumab.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bexarotene.
Agomelatine	The metabolism of Bexarotene can be decreased when combined with Agomelatine.
Albendazole	The metabolism of Albendazole can be increased when combined with Bexarotene.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bexarotene.
Alectinib	The metabolism of Alectinib can be increased when combined with Bexarotene.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Bexarotene.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene.
thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bexarotene.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Bexarotene.
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Bexarotene.
Alosetron	The metabolism of Alosetron can be decreased when combined with Bexarotene.
Alpelisib	The serum concentration of Bexarotene can be decreased when it is combined with Alpelisib.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Bexarotene.
Altretamine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Altretamine.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Bexarotene.
Aminophylline	The metabolism of Aminophylline can be increased when combined with Bexarotene.
Amiodarone	The metabolism of Bexarotene can be decreased when combined with Amiodarone.
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Bexarotene.
Amodiaquine	The metabolism of Amodiaquine can be decreased when combined with Bexarotene.
Amprenavir	The metabolism of Bexarotene can be decreased when combined with Amprenavir.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Bexarotene.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Bexarotene.
Anakinra	The metabolism of Bexarotene can be increased when combined with Anakinra.
Anastrozole	The metabolism of Anastrozole can be decreased when combined with Bexarotene.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Bexarotene.
Anifrolumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Bexarotene.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bexarotene.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Bexarotene.
Antilymphocyte	The risk or severity of adverse effects can be increased when Bexarotene is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Bexarotene.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bexarotene.
Antithrombin III human	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bexarotene.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene.
Apalutamide	The metabolism of Bexarotene can be increased when combined with Apalutamide.
Apixaban	The metabolism of Apixaban can be decreased when combined with Bexarotene.
Apomorphine	The metabolism of Apomorphine can be decreased when combined with Bexarotene.
Apremilast	The metabolism of Bexarotene can be increased when combined with Apremilast.
Aprepitant	The metabolism of Bexarotene can be decreased when combined with Aprepitant.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Bexarotene.
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Bexarotene.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Bexarotene.
Aripiprazole	The metabolism of Aripiprazole can be increased when combined with Bexarotene.
Aripiprazole lauroxil	The metabolism of Aripiprazole lauroxil can be increased when combined with Bexarotene.
Armodafinil	The metabolism of Bexarotene can be decreased when combined with Armodafinil.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Arsenic trioxide.
Artemether	The metabolism of Artemether can be decreased when combined with Bexarotene.
Articaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Articaine.
Asciminib	The metabolism of Bexarotene can be decreased when combined with Asciminib.
Astemizole	The metabolism of Astemizole can be increased when combined with Bexarotene.
AstraZeneca COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bexarotene.
Asunaprevir	The metabolism of Asunaprevir can be decreased when combined with Bexarotene.
Atazanavir	The metabolism of Bexarotene can be decreased when combined with Atazanavir.
Atogepant	The serum concentration of Atogepant can be decreased when it is combined with Bexarotene.
Atorvastatin	The serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.
Atovaquone	The metabolism of Bexarotene can be decreased when combined with Atovaquone.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Bexarotene.
Avapritinib	The metabolism of Bexarotene can be decreased when combined with Avapritinib.
Avatrombopag	The metabolism of Bexarotene can be increased when combined with Avatrombopag.
Axitinib	The metabolism of Axitinib can be increased when combined with Bexarotene.
Azacitidine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Azathioprine.
Azelastine	The metabolism of Azelastine can be decreased when combined with Bexarotene.
Azithromycin	The metabolism of Azithromycin can be increased when combined with Bexarotene.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bexarotene.
Bacillus calmette-guerin	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bexarotene.
Bacillus antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bexarotene.
Baricitinib	The risk or severity of adverse effects can be increased when Bexarotene is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Bexarotene.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Bexarotene.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Beclomethasone dipropionate.
Belatacept	The risk or severity of adverse effects can be increased when Bexarotene is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Bexarotene is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Bexarotene is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Bexarotene.
Bendamustine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bexarotene.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bexarotene.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Benzyl alcohol.
Berotralstat	The metabolism of Bexarotene can be decreased when combined with Berotralstat.
Betamethasone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Betamethasone.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Bexarotene.
Bicalutamide	The metabolism of Bicalutamide can be increased when combined with Bexarotene.
Bimekizumab	The metabolism of Bexarotene can be increased when combined with Bimekizumab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Bexarotene.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bexarotene.
Blinatumomab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Blinatumomab.

Bortezomib	The metabolism of Bortezomib can be increased when combined with Bexarotene.
Bosentan	The metabolism of Bexarotene can be increased when combined with Bosentan.
Bosutinib	The metabolism of Bosutinib can be increased when combined with Bexarotene.
Brentuximab vedotin	The metabolism of Brentuximab vedotin can be increased when combined with Bexarotene.
Brigatinib	The metabolism of Brigatinib can be increased when combined with Bexarotene.
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Bexarotene.
Brodalumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Brodalumab.
Budesonide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Bupivacaine.
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Bexarotene.
Bupropion	The metabolism of Bupropion can be decreased when combined with Bexarotene.
Busulfan	The metabolism of Busulfan can be increased when combined with Bexarotene.
Butacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Butamben.
Cabazitaxel	The metabolism of Cabazitaxel can be increased when combined with Bexarotene.
Cabergoline	The metabolism of Cabergoline can be increased when combined with Bexarotene.
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Bexarotene.
Canakinumab	The metabolism of Bexarotene can be increased when combined with Canakinumab.
Candesartan cilexetil	The metabolism of Candesartan cilexetil can be decreased when combined with Bexarotene.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Bexarotene.
Cannabidiol	The metabolism of Bexarotene can be decreased when combined with Cannabidiol.
Capecitabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bexarotene.
Capmatinib	The serum concentration of Capmatinib can be decreased when it is combined with Bexarotene.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Capsaicin.
Carbamazepine	The metabolism of Carbamazepine can be increased when combined with Bexarotene.
Carboplatin	The serum concentration of Bexarotene can be increased when it is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Bexarotene is combined with Carfilzomib.
Cariprazine	The metabolism of Cariprazine can be increased when combined with Bexarotene.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Bexarotene.
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Bexarotene.
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Bexarotene.
Cenobamate	The serum concentration of Bexarotene can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Cephalexin can be increased when combined with Bexarotene.
Ceritinib	The metabolism of Ceritinib can be increased when combined with Bexarotene.
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Bexarotene.
Certolizumab pegol	The metabolism of Bexarotene can be increased when combined with Certolizumab pegol.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bexarotene.
Chloramphenicol	The risk or severity of adverse effects can be increased when Bexarotene is combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Chloroprocaine.
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Bexarotene.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bexarotene.
Chlorpromazine	The metabolism of Chlorpromazine can be increased when combined with Bexarotene.
Chlorpropamide	The metabolism of Chlorpropamide can be decreased when combined with Bexarotene.
Ciclesonide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ciclesonide.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Bexarotene.
Cimetidine	The metabolism of Bexarotene can be decreased when combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Cinchocaine.
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Bexarotene.
Ciprofloxacin	The metabolism of Bexarotene can be decreased when combined with Ciprofloxacin.
Cisapride	The metabolism of Cisapride can be increased when combined with Bexarotene.
Cisplatin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Bexarotene.
Clarithromycin	The metabolism of Bexarotene can be decreased when combined with Clarithromycin.
Clevidipine	The metabolism of Bexarotene can be decreased when combined with Clevidipine.
Clindamycin	The metabolism of Clindamycin can be increased when combined with Bexarotene.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Clofarabine.
Clomipramine	The metabolism of Clomipramine can be increased when combined with Bexarotene.
Clonazepam	The metabolism of Clonazepam can be increased when combined with Bexarotene.
Clonidine	The metabolism of Clonidine can be increased when combined with Bexarotene.
Clopidogrel	The metabolism of Bexarotene can be decreased when combined with Clopidogrel.
Clostridium tetani	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene.
Clozapine	The risk or severity of neutropenia can be increased when Bexarotene is combined with Clozapine.
Cobicistat	The metabolism of Bexarotene can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Cobimetinib can be increased when combined with Bexarotene.
Cocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Cocaine.
Conivaptan	The metabolism of Bexarotene can be decreased when combined with Conivaptan.
Copanlisib	The metabolism of Copanlisib can be increased when combined with Bexarotene.
Corticotropin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene.
Crizotinib	The metabolism of Crizotinib can be increased when combined with Bexarotene.
Curcumin	The metabolism of Bexarotene can be decreased when combined with Curcumin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bexarotene.
Cyclizine	The metabolism of Bexarotene can be decreased when combined with Cyclizine.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bexarotene.
Cyclophosphamide	The metabolism of Cyclophosphamide can be increased when combined with Bexarotene.
Cyclosporine	Bexarotene may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bexarotene.
Cyproterone acetate	The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Bexarotene.
Cytarabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Bexarotene.
Dabigatran etexilate	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Bexarotene.
Dabrafenib	The serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib.
Dacarbazine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dacarbazine.
Daclatasvir	The metabolism of Daclatasvir can be increased when combined with Bexarotene.
Dacomitinib	The metabolism of Dacomitinib can be increased when combined with Bexarotene.
Dactinomycin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dactinomycin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Bexarotene.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Bexarotene.
Danazol	The metabolism of Bexarotene can be decreased when combined with Danazol.
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Bexarotene.
Dapsone	The metabolism of Dapsone can be decreased when combined with Bexarotene.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bexarotene.
Daridorexant	The metabolism of Daridorexant can be increased when combined with Bexarotene.
Darolutamide	The serum concentration of Darolutamide can be decreased when it is combined with Bexarotene.
Darunavir	The metabolism of Bexarotene can be decreased when combined with Darunavir.

You Might Also Read Duvelisib - Uses, Dosage, Side Effects, Interaction

Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Bexarotene.
Dasatinib	The metabolism of Dasatinib can be increased when combined with Bexarotene.
Daunorubicin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Decitabine.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Bexarotene.
Deflazacort	The serum concentration of Deflazacort can be decreased when it is combined with Bexarotene.
Delafloxacin	The metabolism of Bexarotene can be increased when combined with Delafloxacin.
Delavirdine	The metabolism of Bexarotene can be decreased when combined with Delavirdine.
Demeclocycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Demeclocycline.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Bexarotene.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Bexarotene.
Desogestrel	The therapeutic efficacy of Desogestrel can be decreased when used in combination with Bexarotene.
Desoximetasone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Desoximetasone.
Desvenlafaxine	The metabolism of Bexarotene can be decreased when combined with Desvenlafaxine.
Deucravacitinib	The risk or severity of adverse effects can be increased when Bexarotene is combined with Deucravacitinib.
Dexamethasone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexamethasone.
Dexibuprofen	The metabolism of Dexibuprofen can be decreased when combined with Bexarotene.
Dexrazoxane	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Bexarotene.
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Bexarotene.
Diacerein	The metabolism of Bexarotene can be decreased when combined with Diacerein.
Diazepam	The metabolism of Diazepam can be decreased when combined with Bexarotene.
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Bexarotene.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Bexarotene.
Dienogest	The therapeutic efficacy of Dienogest can be decreased when used in combination with Bexarotene.
Diethylstilbestrol	The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Bexarotene.
Difluocortolone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Difluocortolone.
Digitoxin	The metabolism of Digitoxin can be increased when combined with Bexarotene.
Dihydroergocornine	The metabolism of Dihydroergocornine can be increased when combined with Bexarotene.
Dihydroergocristine	The metabolism of Dihydroergocristine can be increased when combined with Bexarotene.
Dihydroergotamine	The metabolism of Dihydroergotamine can be increased when combined with Bexarotene.
Diltiazem	The metabolism of Bexarotene can be decreased when combined with Diltiazem.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dimethyl fumarate.
Dinutuximab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dinutuximab.
Diosmin	The metabolism of Bexarotene can be decreased when combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Bexarotene.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Diroximel fumarate.
Docetaxel	The metabolism of Docetaxel can be increased when combined with Bexarotene.
Doconexent	The metabolism of Bexarotene can be decreased when combined with Doconexent.
Dofetilide	The metabolism of Dofetilide can be increased when combined with Bexarotene.
Domperidone	The metabolism of Domperidone can be decreased when combined with Bexarotene.
Donepezil	The metabolism of Donepezil can be decreased when combined with Bexarotene.
Doxazosin	The metabolism of Doxazosin can be increased when combined with Bexarotene.
Doxepin	The metabolism of Doxepin can be decreased when combined with Bexarotene.
Doxorubicin	The metabolism of Doxorubicin can be increased when combined with Bexarotene.
Doxycycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Doxycycline.
Dronabinol	The metabolism of Bexarotene can be decreased when combined with Dronabinol.
Dronedarone	The metabolism of Dronedarone can be increased when combined with Bexarotene.
Drospirenone	The therapeutic efficacy of Drospirenone can be decreased when used in combination with Bexarotene.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bexarotene.
Duloxetine	The metabolism of Duloxetine can be decreased when combined with Bexarotene.
Duvelisib	The metabolism of Duvelisib can be increased when combined with Bexarotene.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Dyclonine.
Ebastine	The metabolism of Ebastine can be increased when combined with Bexarotene.
Ebola Zaire vaccine	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bexarotene.
Eculizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Bexarotene.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Bexarotene.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene.
Efavirenz	The metabolism of Bexarotene can be decreased when combined with Efavirenz.
Elagolix	The metabolism of Elagolix can be decreased when combined with Bexarotene.
Eletriptan	The metabolism of Bexarotene can be decreased when combined with Eletriptan.
Elexacaftor	The metabolism of Elexacaftor can be increased when combined with Bexarotene.
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Bexarotene.
Elvitegravir	The metabolism of Bexarotene can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Bexarotene can be increased when combined with Emapalumab.
Enasidenib	The metabolism of Enasidenib can be increased when combined with Bexarotene.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Bexarotene.
Entrectinib	The metabolism of Entrectinib can be increased when combined with Bexarotene.
Enzalutamide	The serum concentration of Bexarotene can be decreased when it is combined with Enzalutamide.
Epinephrine	The metabolism of Bexarotene can be decreased when combined with Epinephrine.
Epirubicin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Epirubicin.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Bexarotene.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Bexarotene.
Eravacycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Eravacycline.
Erdafitinib	The metabolism of Erdafitinib can be increased when combined with Bexarotene.
Ergotamine	The metabolism of Bexarotene can be decreased when combined with Ergotamine.
Eribulin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Eribulin.
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Bexarotene.
Erythromycin	The metabolism of Bexarotene can be decreased when combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bexarotene.
Esketamine	The metabolism of Esketamine can be decreased when combined with Bexarotene.
Estetrol	The therapeutic efficacy of Estetrol can be decreased when used in combination with Bexarotene.
Estradiol	The therapeutic efficacy of Estradiol can be decreased when used in combination with Bexarotene.
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Bexarotene.
Estradiol benzoate	The metabolism of Estradiol benzoate can be increased when combined with Bexarotene.
Estradiol cypionate	The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Bexarotene.
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Bexarotene.
Estradiol valerate	The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Bexarotene.
Estramustine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Estramustine.
Estrone sulfate	The metabolism of Estrone sulfate can be increased when combined with Bexarotene.
Eszopiclone	The serum concentration of Eszopiclone can be decreased when it is combined with Bexarotene.
Etanercept	The metabolism of Bexarotene can be increased when combined with Etanercept.
Ethambutol	The metabolism of Bexarotene can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Bexarotene can be decreased when combined with Ethanol.
Ethinylestradiol	The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Bexarotene.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Ethyl chloride.
Ethynodiol diacetate	The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Bexarotene.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Etidocaine.

Etodolac	The metabolism of Etodolac can be decreased when combined with Bexarotene.
Etonogestrel	The metabolism of Etonogestrel can be increased when combined with Bexarotene.
Etoposide	The metabolism of Etoposide can be increased when combined with Bexarotene.
Etoricoxib	The metabolism of Bexarotene can be decreased when combined with Etoricoxib.
Etravirine	The metabolism of Bexarotene can be decreased when combined with Etravirine.
Everolimus	The metabolism of Everolimus can be increased when combined with Bexarotene.
Felbamate	The metabolism of Bexarotene can be decreased when combined with Felbamate.
Felodipine	The metabolism of Bexarotene can be decreased when combined with Felodipine.
Fenofibrate	The metabolism of Fenofibrate can be increased when combined with Bexarotene.
Filgotinib	The risk or severity of adverse effects can be increased when Bexarotene is combined with Filgotinib.
Finerenone	The therapeutic efficacy of Finerenone can be decreased when used in combination with Bexarotene.
Fingolimod	Bexarotene may increase the immunosuppressive activities of Fingolimod.
Flecainide	The metabolism of Bexarotene can be decreased when combined with Flecainide.
Floxuridine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Floxuridine.
Fluconazole	The metabolism of Bexarotene can be decreased when combined with Fluconazole.
Flucytosine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludarabine.
Fludrocortisone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludrocortisone.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Bexarotene.
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Bexarotene.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Bexarotene.
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Bexarotene.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinolone acetonide.
Fluocinonide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluorometholone.
Fluorouracil	The metabolism of Fluorouracil can be decreased when combined with Bexarotene.
Fluoxetine	The metabolism of Bexarotene can be decreased when combined with Fluoxetine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bexarotene.
Fluprednisolone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluprednisolone.
Flurbiprofen	The metabolism of Flurbiprofen can be decreased when combined with Bexarotene.
Fluticasone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone propionate.
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Bexarotene.
Fluvoxamine	The metabolism of Bexarotene can be decreased when combined with Fluvoxamine.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Bexarotene.
Formoterol	The metabolism of Formoterol can be decreased when combined with Bexarotene.
Fosaprepitant	The metabolism of Fosaprepitant can be increased when combined with Bexarotene.
Fosnetupitant	The metabolism of Bexarotene can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Fosphenytoin can be increased when combined with Bexarotene.
Fusidic acid	The metabolism of Bexarotene can be decreased when combined with Fusidic acid.
Gallium nitrate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Gallium nitrate.
Ganaxolone	The metabolism of Ganaxolone can be increased when combined with Bexarotene.
Gemcitabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Gemcitabine.
Gemfibrozil	The metabolism of Bexarotene can be decreased when combined with Gemfibrozil.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene.
Gestrinone	The therapeutic efficacy of Gestrinone can be decreased when used in combination with Bexarotene.
Gilteritinib	The metabolism of Gilteritinib can be increased when combined with Bexarotene.
Ginkgo biloba	The metabolism of Bexarotene can be decreased when combined with Ginkgo biloba.
Glasdegib	The metabolism of Glasdegib can be decreased when combined with Bexarotene.
Glatiramer	The risk or severity of adverse effects can be increased when Bexarotene is combined with Glatiramer.
Gliclazide	The metabolism of Gliclazide can be decreased when combined with Bexarotene.
Glimepiride	The metabolism of Bexarotene can be decreased when combined with Glimepiride.
Glipizide	The metabolism of Glipizide can be decreased when combined with Bexarotene.
Gliquidone	The metabolism of Gliquidone can be decreased when combined with Bexarotene.
Glyburide	The metabolism of Bexarotene can be decreased when combined with Glyburide.
Golimumab	The metabolism of Bexarotene can be increased when combined with Golimumab.
Guselkumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Guselkumab.

You Might Also Read Desvenlafaxine; Uses, Dosage, Side Effects, Interactions

Irbesartan	The metabolism of Irbesartan can be decreased when combined with Bexarotene.
Irinotecan	The metabolism of Irinotecan can be increased when combined with Bexarotene.
Isavuconazole	The metabolism of Isavuconazole can be increased when combined with Bexarotene.
Isavuconazonium	The metabolism of Bexarotene can be decreased when combined with Isavuconazonium.
Isoniazid	The metabolism of Bexarotene can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Bexarotene can be decreased when combined with Isradipine.
Istradefylline	The metabolism of Istradefylline can be decreased when combined with Bexarotene.
Itraconazole	The metabolism of Bexarotene can be decreased when combined with Itraconazole.
Ivosidenib	The metabolism of Bexarotene can be increased when combined with Ivosidenib.
Ixabepilone	The metabolism of Ixabepilone can be increased when combined with Bexarotene.
Ixazomib	The metabolism of Ixazomib can be increased when combined with Bexarotene.
Ixekizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ixekizumab.
COVID-19 Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Bexarotene.
Japanese encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene.
Ketamine	The metabolism of Ketamine can be decreased when combined with Bexarotene.
Ketoconazole	The metabolism of Bexarotene can be decreased when combined with Ketoconazole.
Ketorolac	The metabolism of Ketorolac can be decreased when combined with Bexarotene.
Lacosamide	The metabolism of Lacosamide can be increased when combined with Bexarotene.
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Bexarotene.
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Bexarotene.
Lefamulin	The metabolism of Lefamulin can be increased when combined with Bexarotene.
Leflunomide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Leflunomide.
Lemborexant	The serum concentration of Lemborexant can be decreased when it is combined with Bexarotene.
Lenalidomide	The risk or severity of adverse effects can be increased when Bexarotene is combined with Lenalidomide.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene.
Lesinurad	The metabolism of Lesinurad can be decreased when combined with Bexarotene.
Levacetylmethadol	The metabolism of Levacetylmethadol can be increased when combined with Bexarotene.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Levobupivacaine.
Levoketoconazole	The metabolism of Bexarotene can be decreased when combined with Levoketoconazole.
Levomilnacipran	The metabolism of Levomilnacipran can be increased when combined with Bexarotene.
Levonorgestrel	The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Bexarotene.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Lidocaine.
Linagliptin	The metabolism of Linagliptin can be increased when combined with Bexarotene.
Linezolid	The risk or severity of adverse effects can be increased when Bexarotene is combined with Linezolid.
Lipegfilgrastim	Bexarotene may increase the myelosuppressive activities of Lipegfilgrastim.
Lomitapide	The metabolism of Lomitapide can be increased when combined with Bexarotene.
Lomustine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Lomustine.
Lonafarnib	The metabolism of Bexarotene can be decreased when combined with Lonafarnib.
Loperamide	The metabolism of Loperamide can be decreased when combined with Bexarotene.
Lopinavir	The serum concentration of Bexarotene can be increased when it is combined with Lopinavir.
Lornoxicam	The metabolism of Lornoxicam can be decreased when combined with Bexarotene.
Losartan	The metabolism of Losartan can be decreased when combined with Bexarotene.
Lovastatin	The metabolism of Bexarotene can be decreased when combined with Lovastatin.
Lumacaftor	The metabolism of Bexarotene can be increased when combined with Lumacaftor.
Lumateperone	The serum concentration of Lumateperone can be decreased when it is combined with Bexarotene.
Lumiracoxib	The metabolism of Lumiracoxib can be decreased when combined with Bexarotene.
Lurbinectedin	The serum concentration of Lurbinectedin can be decreased when it is combined with Bexarotene.
Lymecycline	The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Bexarotene.
Lynestrenol	The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Bexarotene.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Bexarotene.
Manidipine	The metabolism of Bexarotene can be decreased when combined with Manidipine.
Mavacamten	The serum concentration of Bexarotene can be decreased when it is combined with Mavacamten.
Measles virus vaccine	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Bexarotene.
Mechlorethamine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mechlorethamine.
Medroxyprogesterone	The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Bexarotene.
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Bexarotene.
Megestrol acetate	The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Bexarotene.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Bexarotene is combined with Melphalan.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Bexarotene.
Meperidine	The metabolism of Meperidine can be increased when combined with Bexarotene.
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Bexarotene.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mercaptopurine.
Mestranol	The therapeutic efficacy of Mestranol can be decreased when used in combination with Bexarotene.
Metacycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Metacycline.
Metamizole	The risk or severity of myelosuppression can be increased when Metamizole is combined with Bexarotene.
Methadone	The metabolism of Methadone can be decreased when combined with Bexarotene.
Methimazole	The metabolism of Bexarotene can be decreased when combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Bexarotene.
Methoxy polyethylene	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bexarotene.
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Bexarotene.
Methylene blue	The metabolism of Bexarotene can be decreased when combined with Methylene blue.
Methylprednisolone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Methylprednisolone.
Methylprednisone	The metabolism of Methylprednisone can be increased when combined with Bexarotene.
Methysergide	The metabolism of Methysergide can be increased when combined with Bexarotene.
Metreleptin	The metabolism of Bexarotene can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Bexarotene can be decreased when combined with Metronidazole.
Miconazole	The metabolism of Bexarotene can be decreased when combined with Miconazole.
Midostaurin	The metabolism of Bexarotene can be decreased when combined with Midostaurin.
Mifepristone	The metabolism of Mifepristone can be increased when combined with Bexarotene.
Milnacipran	The metabolism of Milnacipran can be increased when combined with Bexarotene.
Minocycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Minocycline.
Mitapivat	The metabolism of Mitapivat can be increased when combined with Bexarotene.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Bexarotene.
Mitotane	The metabolism of Bexarotene can be increased when combined with Mitotane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mitoxantrone.

Montelukast	The metabolism of Montelukast can be decreased when combined with Bexarotene.
Morphine	The metabolism of Morphine can be decreased when combined with Bexarotene.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mosunetuzumab.
Mumps virus strain	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bexarotene.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Bexarotene.
Mycophenolate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mycophenolic acid.
Nabilone	The metabolism of Nabilone can be decreased when combined with Bexarotene.
Nabumetone	The metabolism of Nabumetone can be decreased when combined with Bexarotene.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Bexarotene.
Naloxone	The metabolism of Bexarotene can be decreased when combined with Naloxone.
Naproxen	The metabolism of Naproxen can be decreased when combined with Bexarotene.
Natalizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Natalizumab.
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Bexarotene.
Nefazodone	The metabolism of Bexarotene can be decreased when combined with Nefazodone.
Nelarabine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Nelarabine.
Nelfinavir	The metabolism of Bexarotene can be decreased when combined with Nelfinavir.
Neratinib	The metabolism of Neratinib can be increased when combined with Bexarotene.
Netupitant	The metabolism of Netupitant can be increased when combined with Bexarotene.
Nevirapine	The metabolism of Bexarotene can be decreased when combined with Nevirapine.
Nicardipine	The metabolism of Bexarotene can be decreased when combined with Nicardipine.
Niclosamide	The metabolism of Niclosamide can be decreased when combined with Bexarotene.
Nilotinib	The metabolism of Bexarotene can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Bexarotene can be decreased when combined with Nilutamide.
Nilvadipine	The metabolism of Bexarotene can be decreased when combined with Nilvadipine.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Bexarotene.
Nintedanib	The metabolism of Nintedanib can be increased when combined with Bexarotene.
Nomegestrol	The metabolism of Nomegestrol can be increased when combined with Bexarotene.
Nomegestrol acetate	The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Bexarotene.
Norelgestromin	The metabolism of Norelgestromin can be increased when combined with Bexarotene.
Norethisterone	The therapeutic efficacy of Norethisterone can be decreased when used in combination with Bexarotene.
Norethynodrel	The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Bexarotene.
Norgestimate	The therapeutic efficacy of Norgestimate can be decreased when used in combination with Bexarotene.
Norgestrel	The therapeutic efficacy of Norgestrel can be decreased when used in combination with Bexarotene.
Nortriptyline	The metabolism of Nortriptyline can be increased when combined with Bexarotene.
Noscapine	The metabolism of Bexarotene can be decreased when combined with Noscapine.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bexarotene.
Obinutuzumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Obinutuzumab.
Ocrelizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ocrelizumab.
Ofatumumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ofatumumab.
Olanzapine	The metabolism of Bexarotene can be decreased when combined with Olanzapine.
Olaparib	The metabolism of Olaparib can be increased when combined with Bexarotene.
Oliceridine	The serum concentration of Oliceridine can be decreased when it is combined with Bexarotene.
Olodaterol	The metabolism of Olodaterol can be decreased when combined with Bexarotene.
Omadacycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Omadacycline.
Ombitasvir	The metabolism of Ombitasvir can be decreased when combined with Bexarotene.
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Bexarotene.
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Bexarotene.
Oritavancin	The metabolism of Bexarotene can be decreased when combined with Oritavancin.
Osimertinib	The metabolism of Osimertinib can be increased when combined with Bexarotene.
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Bexarotene.
Oxaliplatin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Oxaliplatin.
Oxandrolone	The metabolism of Bexarotene can be decreased when combined with Oxandrolone.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Oxybuprocaine.
Oxytetracycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Oxytetracycline.
Ozanimod	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ozanimod.
Paclitaxel	The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.
Pacritinib	The serum concentration of Pacritinib can be decreased when it is combined with Bexarotene.
Palbociclib	The metabolism of Palbociclib can be increased when combined with Bexarotene.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Bexarotene.
Palovarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Palovarotene.
Panobinostat	The metabolism of Panobinostat can be increased when combined with Bexarotene.
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Bexarotene.
Parecoxib	The metabolism of Parecoxib can be decreased when combined with Bexarotene.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Bexarotene.
Paroxetine	The metabolism of Bexarotene can be decreased when combined with Paroxetine.
Pazopanib	The metabolism of Pazopanib can be increased when combined with Bexarotene.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bexarotene.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Bexarotene is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bexarotene.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bexarotene.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bexarotene.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Bexarotene is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Bexarotene is combined with Pemetrexed.
Pemigatinib	The metabolism of Pemigatinib can be increased when combined with Bexarotene.
Penicillamine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Penicillamine.
Pentobarbital	The metabolism of Bexarotene can be increased when combined with Pentobarbital.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Bexarotene.
Pentostatin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Pentostatin.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Bexarotene.
Perampanel	The metabolism of Perampanel can be increased when combined with Bexarotene.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bexarotene.
Pexidartinib	The metabolism of Pexidartinib can be increased when combined with Bexarotene.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Bexarotene.
Phenobarbital	The metabolism of Bexarotene can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Phenol.
Phenprocoumon	The metabolism of Phenprocoumon can be increased when combined with Bexarotene.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene.
Phenylbutazone	The metabolism of Bexarotene can be decreased when combined with Phenylbutazone.
Phenytoin	The metabolism of Phenytoin can be decreased when combined with Bexarotene.
Pimavanserin	The metabolism of Pimavanserin can be increased when combined with Bexarotene.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bexarotene.
Pimozide	The metabolism of Pimozide can be increased when combined with Bexarotene.
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Bexarotene

Piroxicam	The metabolism of Piroxicam can be decreased when combined with Bexarotene.
Pitavastatin	The metabolism of Pitavastatin can be decreased when combined with Bexarotene.
Pitolisant	The serum concentration of Bexarotene can be decreased when it is combined with Pitolisant.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bexarotene.
Pomalidomide	The metabolism of Pomalidomide can be increased when combined with Bexarotene.
Ponatinib	The metabolism of Ponatinib can be increased when combined with Bexarotene.
Ponesimod	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ponesimod.
Posaconazole	The metabolism of Bexarotene can be decreased when combined with Posaconazole.
Pralatrexate	The risk or severity of adverse effects can be increased when Bexarotene is combined with Pralatrexate.
Pralsetinib	The metabolism of Bexarotene can be decreased when combined with Pralsetinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Bexarotene.
Prednisolone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisone.
Pretomanid	The metabolism of Pretomanid can be increased when combined with Bexarotene.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Prilocaine.
Primaquine	The metabolism of Bexarotene can be decreased when combined with Primaquine.
Primidone	The metabolism of Bexarotene can be increased when combined with Primidone.
Probenecid	The metabolism of Bexarotene can be decreased when combined with Probenecid.
Procaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Procarbazine.
Progesterone	The metabolism of Progesterone can be increased when combined with Bexarotene.
Proguanil	The metabolism of Proguanil can be decreased when combined with Bexarotene.
Promazine	The metabolism of Promazine can be decreased when combined with Bexarotene.
Promethazine	The metabolism of Bexarotene can be decreased when combined with Promethazine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Proparacaine.
Propofol	The metabolism of Propofol can be decreased when combined with Bexarotene.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Propoxycaine.
Propylthiouracil	The risk or severity of adverse effects can be increased when Bexarotene is combined with Propylthiouracil.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Bexarotene.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Bexarotene.
Quazepam	The metabolism of Quazepam can be decreased when combined with Bexarotene.
Quinidine	The metabolism of Quinidine can be increased when combined with Bexarotene.
Quinine	The metabolism of Quinine can be decreased when combined with Bexarotene.
immune globulin	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bexarotene.
Rabies virus	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bexarotene.
Rabies virus	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bexarotene.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bexarotene.
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Bexarotene.
Ranolazine	The metabolism of Ranolazine can be increased when combined with Bexarotene.
Ravulizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ravulizumab.
Regorafenib	The metabolism of Regorafenib can be increased when combined with Bexarotene.
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Bexarotene.
Retapamulin	The metabolism of Retapamulin can be increased when combined with Bexarotene.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Bexarotene.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Bexarotene.
Ribociclib	The metabolism of Bexarotene can be decreased when combined with Ribociclib.
Rifampicin	The metabolism of Bexarotene can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Bexarotene can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Bexarotene can be increased when combined with Rifapentine.
Rilonacept	The metabolism of Bexarotene can be increased when combined with Rilonacept.
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Bexarotene.
Rimegepant	The metabolism of Rimegepant can be increased when combined with Bexarotene.
Riociguat	The metabolism of Riociguat can be decreased when combined with Bexarotene.
Risankizumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Risankizumab.
Ritonavir	The serum concentration of Bexarotene can be increased when it is combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Bexarotene.
Rivaroxaban	The risk or severity of bleeding can be increased when Rivaroxaban is combined with Bexarotene.
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Bexarotene.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Bexarotene.
Rolapitant	The metabolism of Rolapitant can be increased when combined with Bexarotene.
Rolitetracycline	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Rolitetracycline.
Romidepsin	The metabolism of Romidepsin can be increased when combined with Bexarotene.
Ropeginterferon	The risk or severity of adverse effects can be increased when Bexarotene is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Ropivacaine.
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Bexarotene.
Rosuvastatin	The metabolism of Rosuvastatin can be increased when combined with Bexarotene.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bexarotene.
Roxadustat	The metabolism of Roxadustat can be decreased when combined with Bexarotene.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bexarotene.
Rucaparib	The metabolism of Bexarotene can be decreased when combined with Rucaparib.
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Bexarotene.
Ruxolitinib	The metabolism of Ruxolitinib can be increased when combined with Bexarotene.
Salicylic acid	The metabolism of Salicylic acid can be decreased when combined with Bexarotene.
Saquinavir	The metabolism of Bexarotene can be decreased when combined with Saquinavir.
Recycling	The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Sarecycline.
Sarilumab	The risk or severity of adverse effects can be increased when Bexarotene is combined with Sarilumab.
Satralizumab	The serum concentration of Bexarotene can be decreased when it is combined with Satralizumab.
Secukinumab	The metabolism of Bexarotene can be increased when combined with Secukinumab.
Segesterone acetate	The metabolism of Segesterone acetate can be increased when combined with Bexarotene.
Selegiline	The metabolism of Selegiline can be decreased when combined with Bexarotene.
Selexipag	The metabolism of Selexipag can be decreased when combined with Bexarotene.
Selpercatinib	The serum concentration of Selpercatinib can be decreased when it is combined with Bexarotene.
Selumetinib	The serum concentration of Selumetinib can be decreased when it is combined with Bexarotene.
Sertraline	The metabolism of Bexarotene can be decreased when combined with Sertraline.
Sildenafil	The metabolism of Bexarotene can be decreased when combined with Sildenafil.
Siltuximab	The metabolism of Bexarotene can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Bexarotene can be decreased when combined with Simeprevir.
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Bexarotene.
Siponimod	The metabolism of Siponimod can be increased when combined with Bexarotene.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bexarotene.
Sirolimus	The metabolism of Sirolimus can be increased when combined with Bexarotene.
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Bexarotene.
Sitaxentan	The metabolism of Bexarotene can be decreased when combined with Sitaxentan.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bexarotene.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Bexarotene.
Somatrogon	The metabolism of Bexarotene can be increased when combined with Somatrogon.
Sonidegib	The metabolism of Sonidegib can be increased when combined with Bexarotene.

You Might Also Read Clobetasol Propionate Uses - Indications, Contraindication

Tioguanine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Tioguanine.
Tipranavir	The metabolism of Bexarotene can be decreased when combined with Tipranavir.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Bexarotene.
Tivozanib	The metabolism of Tivozanib can be increased when combined with Bexarotene.
Tixocortol	The risk or severity of adverse effects can be increased when Bexarotene is combined with Tixocortol.
Tocilizumab	The metabolism of Bexarotene can be increased when combined with Tocilizumab.
Tofacitinib	Bexarotene may increase the immunosuppressive activities of Tofacitinib.
Tolazamide	The metabolism of Tolazamide can be decreased when combined with Bexarotene.
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Bexarotene.
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Bexarotene.
Tolvaptan	The metabolism of Tolvaptan can be increased when combined with Bexarotene.
Topotecan	The risk or severity of adverse effects can be increased when Bexarotene is combined with Topotecan.
Torasemide	The metabolism of Torasemide can be decreased when combined with Bexarotene.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Bexarotene.
Trabectedin	The metabolism of Trabectedin can be increased when combined with Bexarotene.
Tramadol	The metabolism of Tramadol can be increased when combined with Bexarotene.
Tranylcypromine	The metabolism of Bexarotene can be decreased when combined with Tranylcypromine.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Bexarotene.
Trastuzumab emtansine	The metabolism of Trastuzumab emtansine can be increased when combined with Bexarotene.
Treprostinil	The metabolism of Treprostinil can be decreased when combined with Bexarotene.
Tretinoin	The risk or severity of adverse effects can be increased when Bexarotene is combined with Tretinoin.
Triamcinolone	The risk or severity of adverse effects can be increased when Bexarotene is combined with Triamcinolone.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Bexarotene.
Triclabendazole	The metabolism of Bexarotene can be decreased when combined with Triclabendazole.
Trifluridine	The risk or severity of adverse effects can be increased when Bexarotene is combined with Trifluridine.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Bexarotene.
Trilostane	The risk or severity of adverse effects can be increased when Bexarotene is combined with Trilostane.
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Bexarotene.
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Bexarotene.
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Bexarotene.
Troglitazone	The metabolism of Bexarotene can be decreased when combined with Troglitazone.
Troleandomycin	The metabolism of Bexarotene can be decreased when combined with Troleandomycin.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Bexarotene.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bexarotene.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bexarotene.
Typhoid Vi	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bexarotene.
Ubrogepant	The serum concentration of Ubrogepant can be decreased when it is combined with Bexarotene.
Ulipristal	The metabolism of Ulipristal can be increased when combined with Bexarotene.
Upadacitinib	The risk or severity of adverse effects can be increased when Bexarotene is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Bexarotene.
Valdecoxib	The metabolism of Bexarotene can be decreased when combined with Valdecoxib.
Valproic acid	Valproic acid may increase the Pseudotumor Cerebri activities of Bexarotene.
Valsartan	The metabolism of Bexarotene can be decreased when combined with Valsartan.
Vandetanib	The metabolism of Vandetanib can be increased when combined with Bexarotene.

Pregnancy and Lactation

US FDA pregnancy category: Not Assigned

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Lactation

Breastfeeding should be discontinued during treatment. Excreted into human milk: Unknown
Excreted into animal milk: Data not available

How should this medicine be used?

Bexarotene comes as a capsule to take by mouth. It is usually taken once a day with food. Take bexarotene at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bexarotene exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not chew the capsules or dissolve them in liquid or in your mouth. If you are unable to swallow the capsules whole, talk to your doctor.

Bexarotene may be harmful if it gets on the skin. Do not touch the capsules or powder from the capsules if they are broken or leaking. If the powder from a broken capsule gets on your skin, wash the area with soap and water immediately and call your doctor.

Your doctor will start you on an average dose of bexarotene and may decrease your dose if you experience side effects or increase your dose if your condition does not improve.

It may take several months or longer before you notice the full benefit of bexarotene. Do not stop taking bexarotene without talking to your doctor.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking bexarotene,

tell your doctor and pharmacist if you are allergic to bexarotene; or any other retinoid, such as acitretin (Soriatane), etretinate (Tegison), isotretinoin (Accutane), or tretinoin (Vesanoid); or any other medications.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone); certain antifungals such as ketoconazole (Nizoral) and itraconazole (Sporanox); cimetidine (Tagamet); clarithromycin (Biaxin); diltiazem (Cardizem); erythromycin (E.E.S., E-Mycin, Erythrocin); fluvoxamine; gemfibrozil (Lopid), HIV protease inhibitors such as indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); insulin and oral medications for diabetes; nefazodone; phenobarbital; phenytoin (Dilantin); rifampin (Rifadin, Rimactane); tamoxifen (Nolvadex); verapamil (Calan); and vitamin A. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with bexarotene, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you drink or have ever drunk large amounts of alcohol. Also, tell your doctor if you have or have ever had pancreatitis; high levels of cholesterol and other fatty substances in the blood; diabetes; cataracts; or gall bladder, thyroid, kidney, or liver disease.
tell your doctor if you are breastfeeding.
ask your doctor about the safe use of alcoholic beverages while you are taking bexarotene. Alcohol can make the side effects of bexarotene worse.
plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Bexarotene may make your skin sensitive to sunlight.

References

https://pubchem.ncbi.nlm.nih.gov/compound/Bexarotene
https://www.cancer.gov/about-cancer/treatment/drugs/bexarotene
https://go.drugbank.com/drugs/DB00307
https://www.webmd.com/drugs/2/drug-17968/bexarotene-oral/details/list-contraindications
https://en.wikipedia.org/wiki/Bexarotene
https://medlineplus.gov/druginfo/meds/a608006.html
https://www.drugs.com/mtm/bexarotene.html
ChEMBL
http://www.ebi.ac.uk/Information/termsofuse.html
https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1023/
ChEMBL Protein Target Tree
https://www.ebi.ac.uk/chembl/g/#browse/targets
Comparative Toxicogenomics Database (CTD)
http://ctdbase.org/about/legal.jsp
https://ctdbase.org/detail.go?type=chem&acc=D000077610
Drug Gene Interaction database (DGIdb)
http://www.dgidb.org/downloads
https://www.dgidb.org/drugs/BEXAROTENE
DrugBank
https://www.drugbank.ca/legal/terms_of_use
Bexarotene
https://www.drugbank.ca/drugs/DB00307
IUPHAR/BPS Guide to PHARMACOLOGY
https://www.guidetopharmacology.org/about.jsp#license
https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807
Guide to Pharmacology Target Classification
https://www.guidetopharmacology.org/targets.jsp
Therapeutic Target Database (TTD)
Bexarotene
http://idrblab.net/ttd/data/drug/details/D0N0RU
CAS Common Chemistry
LICENSE
The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
https://creativecommons.org/licenses/by-nc/4.0/
Bexarotene
https://commonchemistry.cas.org/detail?cas_rn=153559-49-0
ChemIDplus
LICENSE
https://www.nlm.nih.gov/copyright.html
Bexarotene [USAN:INN:BAN]
https://chem.nlm.nih.gov/chemidplus/sid/0153559490
ChemIDplus Chemical Information Classification
https://chem.nlm.nih.gov/chemidplus/
DTP/NCI
https://www.cancer.gov/policies/copyright-reuse
Bexarotene
https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=747528
EPA DSSTox
LICENSE
https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
Bexarotene
https://comptox.epa.gov/dashboard/DTXSID1040619
CompTox Chemicals Dashboard Chemical Lists
https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)
https://echa.europa.eu/web/guest/legal-notice
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
https://echa.europa.eu/information-on-chemicals
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/211742
FDA Global Substance Registration System (GSRS)
https://www.fda.gov/about-fda/about-website/website-policies#linking
BEXAROTENE
https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A61RXM4375
Hazardous Substances Data Bank (HSDB)
BEXAROTENE
https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7453
Human Metabolome Database (HMDB)
http://www.hmdb.ca/citing
Bexarotene
http://www.hmdb.ca/metabolites/HMDB0014452
HMDB0014452_msms_2231131
https://hmdb.ca/metabolites/HMDB0014452#spectra
ChEBI
Bexarotene
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50859
ChEBI Ontology
http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes
https://www.fda.gov/about-fda/about-website/website-policies#linking
BEXAROTENE
https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
FDA Pharmacological Classification
https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
LiverTox
LICENSE
https://www.nlm.nih.gov/copyright.html
Bexarotene
https://www.ncbi.nlm.nih.gov/books/n/livertox/Bexarotene/
NCI Thesaurus (NCIt)
https://www.cancer.gov/policies/copyright-reuse
https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1635
NCI Thesaurus Tree
https://ncit.nci.nih.gov
ClinicalTrials.gov
https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
https://clinicaltrials.gov/
DailyMed
LICENSE
https://www.nlm.nih.gov/copyright.html
BEXAROTENE
https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BEXAROTENE
Drug Induced Liver Injury Rank (DILIrank) Dataset
https://www.fda.gov/about-fda/about-website/website-policies#linking
bexarotene
https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
Nature Chemistry
https://pubchem.ncbi.nlm.nih.gov/substance/134220606
European Medicines Agency (EMA)
https://www.ema.europa.eu/en/about-us/legal-notice
Targretin (EMEA/H/C/000326)
https://www.ema.europa.eu/en/medicines/human/EPAR/targretin
EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/
FDA Orange Book
https://www.fda.gov/about-fda/about-website/website-policies#linking
https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
NORMAN Suspect List Exchange
LICENSE
Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
https://creativecommons.org/licenses/by/4.0/
Bexarotene
NORMAN Suspect List Exchange Classification
https://www.norman-network.com/nds/SLE/
WHO Anatomical Therapeutic Chemical (ATC) Classification
https://www.whocc.no/copyright_disclaimer/
https://www.whocc.no/atc/
ATC Code
https://www.whocc.no/atc_ddd_index/
National Drug Code (NDC) Directory
https://www.fda.gov/about-fda/about-website/website-policies#linking
BEXAROTENE
https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
MassBank of North America (MoNA)
LICENSE
The content of the MoNA database is licensed under CC BY 4.0.
https://mona.fiehnlab.ucdavis.edu/documentation/license
Bexarotene
https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22NAVMQTYZDKMPEU-UHFFFAOYSA-N%22%27
NCI Cancer Drugs
LICENSE
https://www.cancer.gov/policies/copyright-reuse
Bexarotene
https://www.cancer.gov/about-cancer/treatment/drugs/bexarotene
NIPH Clinical Trials Search of Japan
https://rctportal.niph.go.jp/en/
NLM RxNorm Terminology
https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
https://rxnav.nlm.nih.gov/id/rxnorm/233272
Protein Data Bank in Europe (PDBe)
http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9RA
PubChem
https://pubchem.ncbi.nlm.nih.gov
RCSB Protein Data Bank (RCSB PDB)
https://www.rcsb.org/pages/policies
https://www.rcsb.org/
Springer Nature
https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=26061893-682600633
The Cambridge Structural Database
https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=267542
Thieme Chemistry
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=26061893-682600633
Wikidata
LICENSE
CCZero
https://creativecommons.org/publicdomain/zero/1.0/
Bexarotene
https://www.wikidata.org/wiki/Q418192
Medical Subject Headings (MeSH)
https://www.nlm.nih.gov/copyright.html
Bexarotene
https://www.ncbi.nlm.nih.gov/mesh/2028102
MeSH Tree
http://www.nlm.nih.gov/mesh/meshhome.html
Antineoplastic Agents
https://www.ncbi.nlm.nih.gov/mesh/68000970
KEGG
LICENSE
Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license
https://www.kegg.jp/kegg/legal.html
Therapeutic category of drugs in Japan
http://www.genome.jp/kegg-bin/get_htext?br08301.keg
USP drug classification
http://www.genome.jp/kegg-bin/get_htext?br08302.keg
Anatomical Therapeutic Chemical (ATC) classification
http://www.genome.jp/kegg-bin/get_htext?br08303.keg
Target-based classification of drugs
http://www.genome.jp/kegg-bin/get_htext?br08310.keg
Drug Groups
http://www.genome.jp/kegg-bin/get_htext?br08330.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
GHS Classification Tree
http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
PATENTSCOPE (WIPO)
SID 389151879
https://pubchem.ncbi.nlm.nih.gov/substance/389151879
NCBI
https://www.ncbi.nlm.nih.gov/projects/linkout

Bexarotene – Uses, Dosage, Side Effects, Interactions

Mechanism of Action